Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
m decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
1 m » 1 mm (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
m decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
1 m » 1 mm (Expand Search)
-
261
-
262
-
263
Over-expression of LPLUNC1 decreased 5-8F cell proliferation.
Published 2013“…Flow cytometry analysis showed that LPLUNC1 transfection increased the proportion of cells in G1 phase from 53.7% to 69.9% and decreased the proportion of cells in S phase from 31.6% to 19.2%; p<0.01. …”
-
264
Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue.
Published 2017“…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
-
265
OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts.
Published 2019“…After 4 weeks, when the tumor size was approximately 100 mm<sup>3</sup> (T<sub>0</sub>) mice were treated with OCA (0.03% w/w, 30 mg/kg) alone or combined with Cisplatin (2.4 mg/Kg in 100 μl) or Gemcitabine (1.05 mg/Kg in 100 μl) for 5 additional weeks. a) Results are expressed as percent increase in tumor volume at different time points. …”
-
266
-
267
-
268
-
269
Decreased activity of FASII favors the cold growth of the <i>ΔcshA</i> strain.
Published 2020“…<i>fapR</i> mRNA levels were quantified by RT-qPCR using 16S rRNA as reference gene on total RNAs extracted from <i>wt</i> strain (PR01), <i>ΔcshA</i> strain (PR01-ΔcshA), and suppressor strains <i>ΔcshA/accC</i><sup><i>M385V</i></sup> (C51), <i>ΔcshA/accC</i><sup><i>T183I</i></sup> (sup30), <i>ΔcshA/accD</i><sup><i>F253V</i></sup> (sup17), <i>ΔcshA/accD</i><sup><i>A164V</i></sup> (sup16), <i>ΔcshA/birA</i><sup><i>D320F-FsX28</i></sup> (C58), <i>ΔcshA/birA</i><sup><i>R280stop</i></sup> (sup1) and <i>ΔcshA/bioY</i><sup><i>P123R-FsX1</i></sup> (C66), all at exponential growth phase in MH medium at 25°C. n = 5 for <i>ΔcshA</i>, <i>4 for wt</i> and 3 for all others. …”
-
270
-
271
-
272
-
273
-
274
-
275
-
276
-
277
-
278
-
279
-
280